SAR288 has emerged as a novel therapeutic target for COVID-19. This drug compound exhibits significant antiviral properties against SARS-CoV-2, the virus responsible for COVID-19. Preclinical studies have demonstrated that SAR288 can effectively block viral replication in vitro and in vivo. Additionally, SAR288 has shown favorable safety profiles